🇺🇸 FDA
Pipeline program

8 mg aflibercept (BAY 86-5321) (High Dose)

21583

Phase 3 small_molecule completed

Quick answer

8 mg aflibercept (BAY 86-5321) (High Dose) for Diabetic Macular Edema is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Diabetic Macular Edema
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials